Trial Profile
Drug Use Investigation Of Bosutinib For Cml (Post Marketing Commitment Plan)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms BLF
- Sponsors Pfizer
- 02 Feb 2024 Planned End Date changed from 7 Mar 2024 to 22 Feb 2024.
- 02 Feb 2024 Planned primary completion date changed from 7 Mar 2024 to 22 Feb 2024.
- 17 Feb 2023 Planned End Date changed from 7 Aug 2023 to 7 Mar 2024.